


IN THE CLAIMS:

Please cancel claims 8-18 and 21 without prejudice. Please amend claims 1, 2, 3, 4, 5, 6, 7, 19, 20, 23 and 25. Please add claims 26, 27, 28 and 29. Applicants reserve the right to file continuing applications directed to the subject matter of the cancelled claims as well as to the subject matter cancelled from any of the claim amendments below.

Please amend claims 1, 2, 3, 4, 5, 6, 7, 19, 20, 23 and 25 as follows:

1.(Once Amended) A compound having the formula:



wherein $R^1 = CH_2OH$;

R^3 is selected from the group consisting of CO_2R^{20} , $-CONR^7R^8$, and aryl, wherein the aryl substituent is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, alkyl, and OR^{20} ;

R^7 is selected from the group consisting of hydrogen, straight or branched C_{1-15} alkyl and C_{3-8} cycloalkyl, wherein the alkyl substituent is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of aryl and CO_2R^{20} , and wherein the optional aryl substituent is optionally substituted with halo;

R^8 is selected from the group consisting of hydrogen, straight or branched C_{1-15} alkyl and C_{3-8} cycloalkyl;

R^{20} is selected from the group consisting of hydrogen and C_{1-15} alkyl;

and wherein R^2 and R^4 are hydrogen.

2. (Once Amended) The compound of claim 1 wherein R^3 is CO_2R^{20} ; and R^{20} is selected from the group consisting of hydrogen and C_{1-4} alkyl.

3. (Once Amended) The compound of claim 1 wherein R^3 is $CONR^7R^8$; R^7 is selected from the group consisting of hydrogen, straight or branched C_{1-10} alkyl and C_{3-5} cycloalkyl, wherein the alkyl substituent is optionally substituted with from 1 to 2 substituents independently selected from the group consisting of aryl and CO_2OR^{20} ;

R^8 is selected from the group consisting of hydrogen, straight and branched C_{1-3} alkyl and C_{3-5} cycloalkyl; and

R^{20} is selected from the group consisting of C_{1-4} alkyl.

4. (Once Amended) The compound of claim 1 wherein R^3 is aryl, wherein the aryl substituent is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, alkyl and OR^{20} ; and

R^{20} is selected from and the group consisting of C_{1-4} alkyl.

5. (Once Amended) The compound of claim 2 wherein R^3 is CO_2R^{20} ; and R^{20} is selected from the group consisting of hydrogen and C_{1-4} alkyl.

6. (Once Amended) The compound of claim 3 wherein R^7 is selected from the group consisting of hydrogen, C_{1-3} alkyl and cyclopentyl, wherein the alkyl substituent is optionally substituted with from 1 to 2 substituents, independently selected from the group consisting of phenyl and CO_2R^{20} and wherein each optional phenyl substituent is optionally substituted with halo;

R^8 is selected from hydrogen and methyl; and

R^{20} is selected from hydrogen and ethyl.

7. (Once Amended) The compound of claim 4 wherein

R^3 is aryl, wherein the aryl substituent is phenyl optionally substituted with from 1 to 2 substituents independently selected from the group consisting of chloro, methyl and OR^{20} ; and R^{20} is methyl.

A4
concl'd

8 19. (Once Amended) The compound of claim 1 selected from the group consisting of ethyl 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazole-4-carboxylate;
 (4S,2R,3R,5R)-2-{6-amino-2-[4-(4-chlorophenyl)pyrazolyl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol;
 (4S,2R,3R,5R)-2-{6-amino-2-[4-(4-methoxyphenyl)pyrazolyl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol;
 (4S,2R,3R,5R)-2-{6-amino-2-[4-(4-methylphenyl)pyrazolyl]purin-9-yl}-5-(hydroxymethyl)-oxolane-3,4-diol;
 (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide;
 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazole-4-carboxylic acid;
 (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N,N-dimethylcarboxamide;
 (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-ethylcarboxamide;
 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazole-4-carboxamide;
 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-(cyclopentyl)carboxamide;
 (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-[(4-chlorophenyl)methyl]carboxamide, and
 ethyl 2-[(1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)carbonylamino]acetate.

B 9 20. (Once Amended) A method for stimulating coronary vasodilation in a mammal by administering by intravenous bolus injection an amount of a compound of claim 1 that is sufficient to stress the heart and induce a coronary steal situation for the purposes of imaging the heart.

Comprising

A6 ~~23.~~ (Once Amended) A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutical excipients.

A7 ~~25.~~ (Once Amended) The pharmaceutical composition of claim 23 for the treatment of inflammation, in adjunctive therapy with angioplasty, platelet aggregation, and platelet and neutrophil activation.

Please add the following new claims 26 – 29 to the application:

A8 ~~13~~ ~~26.~~ (New) The compound of claim ~~19~~ wherein the compound is (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.

~~14~~ ~~27.~~ (New) The compound of claim ~~19~~ wherein the compound is 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-(cyclopentyl)carboxamide.

~~15~~ ~~28.~~ (New) The compound of claim ~~19~~ wherein the compound is (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-ethylcarboxamide.

~~16~~ ~~29.~~ (New) A method of dilating the coronary vessels of a mammal, as an adjunct to angioplasty, with the pharmaceutical composition of claim ~~23~~.

REMARKS

Claims 1 through 25 were pending in this application as of the August 27, 2002 Official Action. Claims 1, 2, 3, 4, 5, 6, 7, 19, 20, 23 and 25 have been amended; claims 26, 27, 28 and 29 have been added; and claims 8 through 18 and 21 have been cancelled. To assist the Examiner, enclosed with this Reply are Appendix A (a marked up copy of the claims as they pend after this Reply) and Appendix B (a clean copy of the claims as they pend after this reply).